Finch Therapeutics Group is a biopharma company developing therapeutics through the human microbiome in a human-first discovery platform.The company currently has an ongoing Phase 2 FDA clinical trial for recurrent C. difficile infection.
Patents solely owned by Finch:
Lyophilized formulations of microbial therapies
Screened, healthy donors in the manufacture of microbial therapies
Pharmaceutical compositions containing a plurality of Clostridium species
Dean Liang Glettig